PDL BioPharma — Investor Presentation (September 2020)
32 slides from PDL BioPharma's investor presentation, Sep 10, 2020
Slide 1: Management Presentation September 2020
ee i | LENSAR MANAGEMENT PRESENTATION SEPTEMBER 2020 we |
Slide 2: Disclaimer
Disclaimer This presentation includes estimates regarding market and industry data. Unless otherwise indicated, information concerning the industry and the markets in which LENSAR, Inc. (the “Company,” “we,” “our or “us") operates, including management's general expectations, market position, market
Slide 3: Investment Highlights
Investment Highlights Leading Innovator of Femtosecond Cataract Lasers (FLS) ina Growing Cataract Surgery Market * Innovation Leader: Proprietary laser system leads the market in innovation * Disruptive Technology Platform: — Commercially available Streamline® IV - enables optimal treatment of tissu
Slide 4: Cataract is Highest Volume Surgical Procedure Worldwide
_ Cataract is Highest Volume Surgical Procedure Worldwide 29 Million global cataract/refractive lens exchange surgical procedures in 2019 Cataract Procedure Breakdown ECCE/Other Ultrasonic Phacoemulsification (USP) 2024 FLACS forecast in cataract/refractive lens exchange procedures is 1 million 2024
Slide 5: Visually Significant Astigmatism Exists in the Majority of People
Visually Significant Astigmatism Exists in the Majority of People Who Need Cataract Surgery but Remains Uncorrected") Post-Cataract Surgery with Post-Cataract Surgery Pre-Cataract Surge! gery Visually Significant Astigmatism With Astigmatism Corrected “a “ ; * = —_ + Glasses donothelpvision + Glasse
Slide 6: Femtosecond Laser Assisted Cataract Surgery (FLACS) Still Underpenetrated
Femtosecond Laser Assisted Cataract Surgery (FLACS) Still Underpenetrated Worldwide . 2019 Procedure Cataract/RLE * Global market penetration World Region Installations (FLACS procedures) grew to 13% in 2019 United States 1,568 473,536 10.7% * FLACS procedures expected to grow Wester Europe Bet 90,2
Slide 7: Growth Drivers of FLACS Market
Growth Drivers of FLACS Market * Increase in premium procedures * Increased penetration of premium procedures — Driven by clinical evidence of improved outcomes * Emergence of PE-backed ophthalmology groups that can afford lasers and actively seeking ways to increase revenue * Next Gen devices that
Slide 8: Summary of LENSAR's Differentiation
Summary of LENSAR’s Differentiation IntelliAxis Refractive Capsulorhexis® Wireless Transfer of Pre-Op Diagnostic Data 4 Iris Registration and Autom: Cataract Density Imaging Highly Efficient Custom Fragmentation
Slide 9: Surgeon-Designed Ergonomics Fits Seamlessly Into Multi-Environments
Surgeon-Designed Ergonomics Fits Seamlessly Into Multi-Environments + Multiple touch screens provide visibility for surgeon, scrub and circulating nurse + Allows use ina sterile or non-sterile environment » Retracting laser head allows unrestricted access to the treated eye after the laser procedure
Slide 10: Cataract Density Imaging
Cataract Density Imaging Category 1 Cataract Density Imaging: Category 2 We believe only LENSAR automatically categorizes the density of each cataract and determines the location of the nucleus to increase treatment efficiency and potentially decrease Category 3 laser energy used in the eye. LENSAR
Slide 11: IntelliAxis Refractive Capsulorhexis to Guide Toric IOL Alignment
IntelliAxis Refractive Capsulorhexis® to Guide Toric lOL Alignment + WiFi integration with leading diagnostics equipment + Adjusts for cyclorotation, precisely places Toric IOL on the desired axis — visualize intra and post operatively + Facilitates and optimizes IOL alignment along the pre-defined
Slide 12: LENSAR with Streamline Iris Registration
LENSAR with Streamline™ Iris Registration + Iris Registration eliminates the need to manually mark the cornea * Reduces or eliminates transcription and marking errors » In this example, there was a 9.5° clockwise rotation that was detected and compensated during the incision planning phase of the pr
Slide 13: Essence of LENSAR's Differentiation
Essence of LENSAR’s Differentiation IntelliAxis Refractive Capsulorhexis® - Unique and Proprietary Technology IntelliAxis Refractive Capsulorhexis®... * Creates a pair of small tabs on the capsular rim guided by Iris Registration to identify the intended axis as part of the laser Refractive Capsulor
Slide 14: The Surgeon's Perspective on LENSAR Technology
The Surgeon’s Perspective on LENSAR Technology “What | enjoy is the refractive outcomes and the predictability that the LENSAR® Laser System now affords me as it relates to astigmatism correction with toric IOL placement. The IntelliAxis Refractive Capsulorhexis® places refractive marks on the capsu
Slide 15: Unmet Need and Room for Improvement
Unmet Need and Room for Improvement Spectacle-independence must include management of astigmatism Number of Patients Prevalence of igmatism Prior to Cataract Surgery 70-90% of patients have treatable astigmatism; the majority of these remain uncorrected* 19.1% 1800 1350 17.196} Aa N=6,000 1200 ‘Warr
Slide 16: Disruptive Astigmatism Management Capability
Disruptive Astigmatism Management Capability Current solutions are sub-optimal; for 50% of pre-existing, no attempt to treat LASIK, PRK — Significant contraindications (dry-eye), flaps — Secondary procedures take additional patient and surgeon time, visual recovery time, added cost Al incisions (man
Slide 17: LENSAR: Tools to Enable Superior Outcomes
LENSAR: Tools to Enable Superior Outcomes P< 0001 ao 15D Fhe-op Mean Reve (jade: Pastp Men Rev (inde (w= 60) (W=60) 0 02 oo - P0001 ono FreopMeon aot Cyider Fstop Mean Reka Ginder ) ce) r 1010 Postoperative Results + 98% of eyes with toric IOL treatment were <0.5 D + Oeyes had IOL misalignment or ad
Slide 18: wer 81,085
* $08,030 ro" ] & no wer 81,085 63,175 49,769 38,528 2015 216 2017 218 2019
Slide 19: LENSAR Laser Utilization Significantly Higher than Other Femto Systems
LENSAR Laser Utilization Significantly Higher than Other Femto Systems Procedure volume grew 30% YOY since 2016 Avg. per LENSAR Avg. Comparison to World Region Installed Device!) | Procedures per Laser Industry Average LENSAR installed systems | 610 Uaiadl Seated 302 0088 performed 79% more procedur
Slide 20: ALLY — All-in-One Femto Phaco Device
ALLY™ — All-in-One Femto Phaco Device We are developing a compact, integrated workstation with state-of-the-art attributes of a LENSAR system AND a phacoemulsification system Anticipated benefits of our design: * Easily replace older technology — Configured anywhere in the operating room; increasing
Slide 21: ALLY — Phaco / Industrial Design
ALLY™ — Phaco / Industrial Design Latest ALLY™ Working Prototype: ALLY™ Industrial Design: 24
Slide 22: Summary of Key Findings: LENSAR ALLY Third Party US Physician Survey
Summary of Key Findings: LENSAR ALLY™ Third Party US Physician Survey Market Research Project Overview * Third party survey with results from 122 US cataract surgeons to assess perceptions regarding FLACS and LENSAR ALLY™ product concept, to inform ALLY™ revenue forecast Key Findings « 40% said that
Slide 23: Financial Highlights
Financial Highlights * Strong YOY double digit revenue growth through 2019; resilient revenues in 2020 even with impact from COVID ° 79% of 2019 revenues from recurring sources!) * 2017 - 2019 Revenue CAGR: “22% * Net loss and EBITDA reflect impact of increase in R&D and manufacturing to support ALL
Slide 24: Strong Pre-COVID Revenue Growth; R&D Investment Driven by ALLY
Strong Pre-COVID Revenue Growth; R&D Investment in 2 Driven by ALLY™ Annual H1 $ in millions 2018 2019 2019 2020 Revenue $24.4 $30.5 $14.0 $11.0 % Growth 18%” 25% - (22%) Net income / (loss) ($12.6) ($14.7) ($6.4) ($8.2) EBITDA” ($4.7) ($8.8) ($3.4) ($5.5) Plus: PDL Allocations” 5.0 44 23 28 Less: E
Slide 25: LENSAR COVID Update
LENSAR COVID Updat YoY Growth 1.2020 22.2020 Key Commentary: Revenue YoY Growth * In Q4, US performed well until March; Asi impacted the most us 178% (289%) ase 7 Coe (252%). In Q2, US hit hardest, albeit less impacted than Asia in QU, and Asia Germony/Other (97%) (13.9%) began to return Total TL5%)
Slide 26: Medium Term Performance Objectives
Medium Term Performance Objectives * Revenue growth in excess of market — 20%+ target YoY growth — 2022 revenue target in $40mm range ° Gross margins — Low 60%+ after LENSAR’s ALLY™ is introduced and at scale * Q1 2022 target filing for ALLY™ 510(k) clearance ° 2H 2022 target launch of ALLY™ 26
Slide 27: Significant Opportunity to Expand Footprint by Increasing Commercial Infrastructure
Significant Opportunity to Expand Footprint by Increasing Commercial Infrastructure LENSAR Installed Base by Country Key Commercial Details Global Installed Base: 216 Service engineers: 6 (CA, FL, IL, NJ, TX, Wi) Us Sales Reps: = 3 asof Dec. 2019 (IL, TX, VA) — 62)as of Jan. 2020 (FL, IL, IN, TX, VA
Slide 28: LENSAR's Leadership has Deep Expertise in Cataract Surgery
LENSAR’s Leadership has Deep Expertise in Cataract Surgery and Device Development and Commercialization Management Nicholas Curtis Alan Connaughton Thomas Staab Chief Executive Officer Chief Operating Officer Chief Financial Officer Previous Experience: Previous Experience: Previous Experience: Wave
Slide 29: Investment Highlights
Investment Highlights * Established innovation leader with highly respected leadership team and board of directors * Disruptive technology platform with Streamline® IV; developing next-generation workstation with ALLY™ — Streamline® IV - enables optimal treatment of tissue-specific cataract and mana
Slide 30: Appendix
APPENDIX
Slide 31: Broad and Deep Intellectual Property Portfolio
Broad and Deep Intellectual Property Portfolio LENSAR Augmented Reality platform, fragmentation, patient interface fully covered * Royalty-free licenses for blocking patents * Issued patents: 29 U.S. and 69 foreign as of June 16, 2020 * Pending patents: 26 pending U.S., 30 pending foreign and one pe
Slide 32: Non-GAAP Reconciliation
Non-GAAP Reconciliation Annual 1H 000s 2018 2019 2019 2020 Net Income / (Loss) ($12,593) ($14,657) ($6,371) ($8,183) Plus: Income tax expense 20 0 0 0 Less: Other income, net (64) (58) (28) (34) Plus: Interest expense 3,321 2,001 953 1,275 Plus: Depreciation 3,453 2,639 1,495 808 Plus: Amortization
PDL Biopharma — Investor Presentation (September 2020) on 6ix